Schad Friedemann, Thronicke Anja, Hofheinz Ralf-Dieter, Klein Reinhild, Grabowski Patricia, Oei Shiao Li, Wüstefeld Hannah, Grah Christian
Network Oncology Registry, Research Institute Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany.
Interdisciplinary Oncological Centre, Hospital Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany.
Pharmaceuticals (Basel). 2024 Dec 18;17(12):1713. doi: 10.3390/ph17121713.
Recent advancements in cancer treatment have shown the potential of immune checkpoint blockade (ICB) plus L. therapy in improving survival rates for patients with advanced or metastatic non-small-cell lung cancer (NSCLC). The objective of this study was to investigate factors associated with improved survival in NSCLC patients treated with a combination of ICB and abnobaViscum. : Patients with advanced or metastatic NSCLC from the accredited Network Oncology registry were included in this real-world data study adhering to ESMO-GROW criteria with ethics approval. Survival outcomes were compared between patients receiving ICB therapy alone versus those receiving combinational ICB plus abnobaViscum therapy using Kaplan-Meier and multivariable Cox proportional hazard analysis. : Among 300 patients (median age 68 years; male/female ratio 1.19), 222 received ICB alone (CTRL group) and 78 received combinational therapy (COMB group). Overall survival was significantly prolonged in the COMB group by 7 months compared to CTRL (13.8 months vs. 6.8 months, = 0.005) with a survival rate of 16.5% in the COMB group vs. 8.0% in the CTRL group. In programmed death-ligand 1 positive (≥1%) patients treated with first-line ICB, the addition of abnobaViscum reduced the adjusted hazard of death by 75% (aHR: 0.25; 95%CI: 0.11-0.60, = 0.02). : The addition of abnobaViscum to ICB is significantly associated with improved survival in patients with advanced or metastatic NSCLC patients, irrespective of age, stage, Eastern cooperative oncology group status, surgery, or radiation. Potential mechanisms include immune modulation, reduced primary ICB resistance, and tumor microenvironment modifications. The findings warrant further validation in randomized controlled trials or registry-based randomized controlled trials. Trial registration: The study was registered (DRKS00013335).
癌症治疗的最新进展表明，免疫检查点阻断（ICB）联合L.疗法在提高晚期或转移性非小细胞肺癌（NSCLC）患者生存率方面具有潜力。本研究的目的是调查接受ICB与欧洲七叶树联合治疗的NSCLC患者生存率提高的相关因素。方法：本项真实世界数据研究纳入了来自认可的网络肿瘤登记处的晚期或转移性NSCLC患者，遵循ESMO-GROW标准并获得伦理批准。使用Kaplan-Meier法和多变量Cox比例风险分析比较单独接受ICB治疗的患者与接受ICB联合欧洲七叶树治疗的患者的生存结局。结果：在300例患者（中位年龄68岁；男女比例1.19）中，222例单独接受ICB治疗（对照组），78例接受联合治疗（联合组）。与对照组相比，联合组的总生存期显著延长7个月（13.8个月对6.8个月，P = 0.005），联合组生存率为16.5%，对照组为8.0%。在接受一线ICB治疗的程序性死亡配体1阳性（≥1%）患者中，添加欧洲七叶树可使调整后的死亡风险降低75%（aHR：0.25；95%CI：0.11 - 0.60，P = 0.02）。结论：在ICB基础上加用欧洲七叶树与晚期或转移性NSCLC患者生存率提高显著相关，与年龄、分期、东部肿瘤协作组状态、手术或放疗无关。潜在机制包括免疫调节、降低原发性ICB耐药性以及肿瘤微环境改变。这些发现值得在随机对照试验或基于登记处的随机对照试验中进一步验证。试验注册：该研究已注册（DRKS00013335）
